The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.
This single-dose, double-blind, random allocation, sham-control, clinical trial will recruit spontaneously breathing newborns with RDS stable on non-invasive nasal respiratory support. Enrolled clinical study subjects will be randomly allocated to receive respiratory air with Infasurf® (Intervention Arm) or respiratory air alone (Sham Control Arm) through the InfasurfAero™. The objectives of this clinical study are to i) assess the effectiveness of a single dose of Infasurf administered through the InfasurfAero in preventing CPAP failure, and ii) assess the safety of Infasurf administered through the InfasurfAero. Subjects will be enrolled at one of 10+ sites. 7 sites are currently recruited.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
220
A single dose of Calfactant administered by pacifier interface by inhalation via the Infasurf Aero nebulizer at 6ml/kg.
St. Josephs Hospital and Medical Center
Phoenix, Arizona, United States
RECRUITINGPhoenix Children's
Phoenix, Arizona, United States
RECRUITINGCPAP failure and or death
CPAP failure is defined as a respiratory severity score (RSS) (MAP x FiO2) \>2.5 on two consecutive assessments at least 30 minutes apart, or an RSS \> 2.4 and one or more of the following: (i) Silverman-Andersen respiratory severity score (https://www.thecalculator.co/health/Silverman-Score-Calculator-1125.html) of ≥ 5 despite respiratory support. (ii) Severe apnea (2 or more episodes per hour, or 1 or more episodes requiring manual positive pressure ventilation). (iii) Respiratory acidosis (pCO2 \> 65 with a pH \< 7.2 on blood gas). RSS will be the primary indicator of CPAP failure. However with the addition of the Silverman-Anderson scores, severe apnea and respiratory acidosis, CPAP failure may occur earlier than solely defined by RSS score.
Time frame: Within 1st week of age
Chronic lung disease and or death
Chronic lung disease is defined as altitude adjusted oxygen requirement at 36 weeks post menstrual age.
Time frame: 36 weeks post menstrual age (PMA).
Incidence of MV
Incidence of Mechanical Ventilation
Time frame: 36 weeks PMA
Duration of MV
length of time of Mechanical Ventilation
Time frame: 36 weeks PMA
Incidence of intubation
Any occurrence of tracheal intubation
Time frame: 36 weeks PMA
Incidence of invasive surfactant replacement therapy
any occurrence of liquid surfactant administration via and endotracheal tube
Time frame: 72 hours post birth
Duration of non-invasive support
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Sharp Mary Birch Hospital for Women & Newborns
San Diego, California, United States
RECRUITINGUniversity of Florida -Jacksonville
Jacksonville, Florida, United States
RECRUITINGKapi'olani Medical Center for Women & Children
Honolulu, Hawaii, United States
RECRUITINGJersey Shore University Medical Center
Neptune City, New Jersey, United States
RECRUITINGSisters of Charity Hospital
Buffalo, New York, United States
RECRUITINGWestern TN- Jackson-Madison County General Hospital
Jackson, Tennessee, United States
RECRUITINGUtah Valley Hospital
Provo, Utah, United States
RECRUITINGUnity Point Meriter
Madison, Wisconsin, United States
RECRUITINGLength of time of respiratory support other than Intubation
Time frame: 36 weeks PMA
Duration of supplemental oxygen
Length of time any oxygen is administered.
Time frame: 36 weeks PMA